Grants per year
Search results
-
Finished
Prot #EZH-108: A Phase 1, Open-Label Multi-Dose Two-Part Study to Characterize the Effects of a Strong CYP3A4 Inhibitor on the Steady-State Pharmacokinetics of Tazemetostat (EPZ-6438), And The Effects Of A Strong CYP3A4 Inducer on the Steady- State Pharma
Mahalingam, D. (PD/PI)
Medpace Clinical Research LLC, Epizyme, Inc.
11/2/20 → 11/2/23
Project: Research project
-
Prot #EZH-1201: A Phase I, Open-Label Multi-Dose Pharmacokinetic and Safety Study of Oral Tazemetostat in Subjects With Moderate And Severe Hepatic Impairment With Advanced Malignancies
Mahalingam, D. (PD/PI)
Pharmaceutical Research Associates, Inc., Epizyme, Inc.
7/8/20 → 7/8/23
Project: Research project
-
Prot #BNT411-01: Phase 1/2a, First-In-Human, Open-label, Dose-escalation Trial With Expansion Cohorts To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Efficacy Of BNT411 As A Monotherapy In Patients With Solid Tumors And In Combinat
Mahalingam, D. (PD/PI)
ICON plc, BioNTech Small Molecules GmbH
5/27/20 → 5/27/23
Project: Research project
-
Prot #Pevonedistat-1015: A Phase 1 Study to Evaluate the Effects of Rifampin on Pharmacokinetics of Pevonedistat in Patients with Advanced Solid Tumors
Mahalingam, D. (PD/PI)
PRA Health Sciences, Millennium Pharmaceuticals, Inc.
11/28/18 → 11/28/21
Project: Research project
-
Prot #19774: A multicenter Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of the combination of rogaratinib and copanlisib in patients with FGFR-positive, local
Mahalingam, D. (PD/PI)
Bayer HealthCare Pharmaceuticals, Inc.
10/18/18 → 5/19/21
Project: Research project
-
Prot #I35316/NU RP17I03: A Phase Ib/ II Study of Sorafenib and Pembrolizumab in Advanced Hepatocellular Cancer (HCC)
Mahalingam, D. (PD/PI)
Roswell Park Cancer Institute, Merck Sharp & Dohme Corporation
8/20/18 → 8/20/24
Project: Research project
-
Prot #VT1021-01: A Phase 1 Study Evaluating the Safety, Pharmacology, and Preliminary Activity of VT1021 in Patients with Advanced Solid Tumors
Mahalingam, D. (PD/PI)
Syneos Health, Inc., Vigeo Therapeutics, Incorporated
7/17/18 → 7/17/24
Project: Research project
-
Prot #NU 18I01: A Phase 2 study of pembrolizumab in combination with pelareorep in patients with advanced pancreatic adenocarcinoma
Mahalingam, D. (PD/PI)
7/5/18 → 7/5/24
Project: Research project
-
Prot #PUMA-NER-5201: An Open-Label, Phase 2 Basket Study Of Neratinib In Patients With Solid Tumors With Somatic Activating HER Mutations
Mahalingam, D. (PD/PI)
Precision Oncology, LLC, Puma Biotechnology, Inc.
5/9/18 → 5/9/24
Project: Research project
-
Prot #LYC-55716-1001: A Phase 1/2A, Multicenter, Open-Label Study of LYC-55716 in Adult Subjects with Locally Advanced or Metastatic Cancer
Mahalingam, D. (PD/PI)
PRA Health Sciences, Lycera Corp.
4/19/18 → 4/19/21
Project: Research project
-
Prot #CPDR001XUS01: Modular Phase 2 Study to Link Combination Immune-Therapy to Patients with Advanced Solid and Hematologic Malignancies Module 9: PDR001 Plus LAG525 for Patients with Advanced Solid and Hematologic Malignancies
Mahalingam, D. (PD/PI)
United BioSource LLC, Novartis Pharmaceuticals Corporation
2/23/18 → 2/28/21
Project: Research project
-
Prot #BAY 1163877/16443: An Open Label, Non-Randomized, Phase I Dose Escalation Study To Characterize Safety, Tolerability, Pharmacokinetics And Maximum Tolerated Dose of BAY 1163877 in Subjects With Refractory, Locally Advanced Or Metastatic Solid Tumors
Carneiro Filho, B. A. (PD/PI) & Mahalingam, D. (PD/PI)
Bayer HealthCare Pharmaceuticals, Inc.
6/21/17 → 8/31/22
Project: Research project
-
Prot #CA209649: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination with Oxaliplatin Plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or
Mahalingam, D. (PD/PI)
6/13/17 → 6/13/24
Project: Research project